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Abstract 
TRIB2 is a potent oncogene, elevated in a subset of human acute myeloid leukaemias (AML) 
with a mixed myeloid/lymphoid phenotype and NOTCH1 mutations. Although rare in AML, 
activating NOTCH1 mutations occur in 50% of all T-acute lymphoblastic leukaemias (T-
ALL). TRIB2 is a NOTCH1 target gene that functions in the degradation of key proteins and 
modulation of MAPK signaling pathways, implicated in haematopoietic cell survival and 
proliferation. We show that TRIB2 expression level is highest in the lymphoid compartment 
of normal haematopoietic cells, specifically in T cells. Analysis of TRIB2 expression across 
16 different subtypes of human leukaemia demonstrated that TRIB2 expression was higher in 
ALL phenotypes versus all other phenotypes including AML, CLL, MDS and CML. A T cell 
profile was distinguished by high TRIB2 expression in normal and malignant 
haematopoiesis. High TRIB2 expression was seen in T-ALL with normal karyotype and 
correlated with NOTCH signalling pathways. In a pediatric patient T-ALL cohort high 
TRIB2 expression correlated with NOTCH1/FBXW7 mutations, strongly linking NOTCH1 
activation and high TRIB2 expression in paediatric T-ALL. The relationship between TRIB2 
and T cell signaling pathways uniquely identifies leukaemia subtypes and will be useful in 
the advancement of our understanding of T cell and ALL biology.  
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Introduction 
Acute leukaemias of the lymphoid and myeloid lineage (ALL and AML) are the most 
common forms of childhood and adult leukaemia respectively. ALL is classified into genetic 
subtypes of the B and T lineage (B-ALL and T-ALL) according to cytogenetically defined 
chromosomal aberrations and genetic mutations. These important hallmarks of ALL disease 
are valuable for guiding treatment strategies of patients. The prognosis of T-ALL in children 
and adults has improved in recent years due to intensified therapies. However long-term 
remission figures suggest that there is still much to be gained with advancing our 
understanding of T-ALL biology (Kraszewska et al, 2012). 
T-ALL accounts for 15% of paediatric and 25% of adult ALLs and these can be subdivided 
into certain classes based on the expression profiles of certain oncogenes (Ferrando et al, 
2002), amongst which are TLX1 (HOX11), TAL1, LYL1, and LM01/2. NOTCH1 is the most 
frequently mutated gene in T-ALL with activating NOTCH1 mutations occuring in 50% (34-
71%) of all adult and childhood T-ALL patients and in rare AML cases (Breit et al, 2006; 
Kraszewska et al, 2012; Weng et al, 2004; Wouters et al, 2007). The NOTCH1 gene encodes 
a transmembrane receptor that is activated through ligand binding, resulting in a series of 
proteolytic events releasing the intracellular portion of NOTCH1 from the plasma membrane 
into the nucleus (Aster et al, 2011). Most NOTCH1 mutations occur in the heterodimerisation 
domain (HD) and proline-glutamic acid-serine-threonine (PEST) domains. These mutations 
lead to the ligand-independent activation of NOTCH1 and decrease the degradation of 
intracellular NOTCH1 respectively, leading to upregulated NOTCH1 activation. FBXW7 is a 
component of ubiquitin ligase complex that induces the degradation of NOTCH1. Loss-of-
function mutations in FBXW7 are frequently found in T-ALL with a prevalence of 8-16% 
(Kraszewska et al, 2012) which lead to the inability of FBXW7 to target NOTCH1 for 
degradation resulting in the prolonged half-life of active NOTCH1 (O'Neil et al, 2007; 
Thompson et al, 2007). 
Despite significant progress made in recent years in our understanding of NOTCH1 
mutations in T-ALL and T-ALL biology, the prognostic significance of NOTCH1 and/or 
FBXW7 mutations remains inconclusive in T-ALL. A good clinical outcome for paediatric 
patients harbouring NOTCH1 and/or FBXW7 mutations was reported in the ALL-BFM 2000 
study (Breit et al, 2006) and in the JACLS ALL-97 and NHL-98 study (Park et al, 2009). 
Contrary to these it was reported that NOTCH1 mutations and/or FBXW7 mutations were not 
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predictive of outcome in paediatric (Erbilgin Y, 2010; van Grotel et al, 2007) or adult (Baldus 
et al, 2009) T-ALL. NOTCH1 mutations have been shown to correlate with poor prognosis in 
adults but not in paediatric patients in an independent study (Zhu et al, 2006). 
TRIB2 was originally identified as a direct NOTCH1-regulated transcript in T-ALL 
(Wouters et al, 2007) and recently as a target of PITX1, a leukemic gene recurrently 
activated in T-ALL (Nagel et al, 2011). TRIB2 proteins are emerging as important 
modulators of signalling and differentiation pathways through the modulation of MAPK 
signalling and C/EBP family members (Yokoyama & Nakamura, 2011). TRIB2 can bind and 
target proteins for degradation through the proteasome and these functions are involved in 
myeloid differentation and cell survival pathways. Overexpression of Trib2 in 
haematopoietic progenitors drives robust murine AML with a relatively short latency of 6 
months and can cooperate with HOXA9 to accelerate AML in a murine bone marrow 
transplant model (Keeshan et al, 2006; Keeshan et al, 2008). Subsequently a survey of 
TRIB2 mRNA expression in human AML patient samples identified elevated TRIB2 
expression in a specific subset of tumours with dysregulated C/EBPalpha and NOTCH1 
mutations (Keeshan et al, 2006; Wouters et al, 2007). This subset of AML patients had a 
myeloid/lymphoid phenotype as determined by markers of the T cell lineage (Wouters et al, 
2007). 
In this study, we evaluated TRIB2 expression in haematopoiesis and in myeloid and 
lymphoid leukaemias. Our results show that high TRIB2 expression correlates with T-ALL, 
and specifically with normal karyotype T-ALL and ALL with t(1:19). Profiling of ALL 
subsets with high TRIB2 expression reveal a correlation with T cell receptor (TCR) 
signalling pathways, and specifically T-ALL correlates with NOTCH signalling pathways. 
Furthermore TRIB2 is normally expressed at the highest level in the lymphoid compartment, 
specifically in T cells. The analysis of the expression of TRIB2 in a cohort of paediatric T-
ALL revealed a significant correlation between high TRIB2 expression and NOTCH1 
activation. Our findings demonstrate that high TRIB2 expression is an important marker of a 
subset of adult and paediatric T-ALLs, linking strongly with activated T cell pathways. Our 
data provide evidence for a potential role of TRIB2 in the development of the T cell 
phenotype of ALL and specifically with activated NOTCH1 phenotypes.  
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Methods 
Patient Samples 
Bone marrow (BM) and peripheral blood (PB) samples were obtained from the Turkish BFM 
Study Group from 60 pediatric T-ALL patients. The study was approved by the ethical 
committee of Istanbul Medical Faculty, Istanbul University and informed consents were 
obtained from all participating patients as previously described (Erbilgin Y, 2010). The 
median age of diagnosis was 9 years (range 22 days- 16 years). The male to female ratio was 
2.7:1. 
RNA isolation and cDNA synthesis 
BM and PB samples were stored at -80°C after homogenisation in RLT buffer. Total RNA 
was isolated using Qiagen Rneasy Plus Mini Kit (Qiagen, GmbH, Germany) and treated with 
DNAse (MBI Fermentas, Germany) to remove DNA contamination. cDNA was synthesised 
using 1ug of total RNA,  random hexamers and MMLV reverse transcriptase in accordance 
with manufacturers  protocol (MBI Fermentas Life Sciences, Lithuania). 
Detection of NOTCH1 and FBXW7 mutations 
Exons 7, 8, 9, 10, 11 and WD-40 of FBXW7 and HD-N (exon26), HD-C (exon 27) and PEST 
domain (exon 34) of NOTCH1 were amplified and denaturing high-performance liquid 
chromatography technique was performed in addition to direct sequencing as previously 
described (Erbilgin Y, 2010).  
Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed using SYBR Green master-mix on light cycler 480 instrument 
(Roche Applied Sciences, Manheim, Germany). 18s and ABL genes were selected for the 
house keeping normalization genes. Further primer details provided in supplementary data. 
Statistical analysis 
TRIB2 expression levels were normalised to 18s and ABL genes and RPMI 8402 T-ALL cell 
line was used as positive internal control. Each sample was normalised to the calibrator 
sample in accordance with 2-ΔΔCT method (Livak and Schmittgen, 2001). TRIB2 
expression level in wildtype and mutant NOTCH1/FBXW7 T-ALLs were compared by 2-
tailed student t-test. The 95% confidence value interval for differences in expression between 
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the groups was obtained. For the box plots one-way ANOVA with Dunnett’s post test was 
used to test the significance between TRIB2 levels in each leukemia phenotype and 
normal bone marrow. All statistics were performed using GraphPad Prism5. 
Bioinformatic Analyses 
Expression profiles of the leukaemia subtypes were generated from the MILE Study 
(GSE13204) (Haferlach et al, 2010). Two TRIB2 probe sets (202478_at and 202479_s_at) 
were present on the arrays. For each TRIB2 probe we analysed the expression levels of 
TRIB2 and values for each leukaemia subtype and normal bone marrow were plotted 
on a box plot with max and min whiskers using GraphPad and scaled to reflect the 
expression values in the Affymetrix chip. To determine the nearest-neighbours in the 
MILE dataset for ALL, each patient sample was separated based on whether TRIB2 
expression was below the median expression of both probe sets (labelled 0) or above the 
median expression in both probe sets (labelled 2). A one-way ANOVA analysis was then 
preformed to determine genes with significantly different expression between the 0 and 2 
group (above versus below the median for both probe sets). Unsupervised hierarchical 
clustering of these the top 1000 differentially expressed genes (p<5x10-12) was then 
performed using Partek Genomics Suite (Version 6.6). GSEA with 1000 permutations was 
carried out using the GSEA program suite (version 2.07) available from the Broad Institute 
(http://www.broadinstitute.org/gsea/index.jsp) (Subramanian et al, 2005). For GSEA 
analysis the dataset was first collapsed to max probe expression, genes were then ranked 
using the Pearson correlation matrix with continuous phenotype labels for TRIB2, and run 
against the canonical pathway subset available for GSEA analyses in the Molecular 
Signalling Database (MSigDB) (v3.0), which include gene sets compiled from a number of 
sources (BioCarta, KEGG, Reactome, signalling gateway and more). GSEA was also run 
against the 80 modules of strongly coexpressed genes identified by Novershtern at al. in the 
haematopoietic cell lineages (Novershtern et al, 2011). GSEA with continuous phenotype 
labels was carried out for TRIB2 specifically in T-ALL of the MILE study and run against a 
set of NOTCH signalling pathways derived from the MSigDB. 
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Results 
Overexpression of Trib2 in a murine model leads to AML with a myeloid phenotype 
exclusively. However in the human disease, elevated TRIB2 is associated with AML with a 
mixed myeloid and lymphoid phenotype (Wouters et al, 2007). Since we first identified 
TRIB2 as a NOTCH1 target gene in a T-ALL cell line (Keeshan et al, 2006), we asked 
whether TRIB2 plays a role in other types of human leukaemia. The collaborative 
Microarray Innovations in Leukaemia (MILE) study program incorporates gene expression 
profiles of 16 acute and chronic leukaemia subclasses, myelodysplastic syndromes (MDSs), 
and control groups that includes nonmalignant disorders and normal bone marrow from 2096 
patients (Haferlach et al, 2010). We analysed the expression levels of TRIB2 across the range 
of different leukaemias in this dataset. TRIB2 was expressed at significantly higher levels in 
T-ALL (with normal karyotype, p<0.001) and in (pre-B) ALL with t(1;19) (p<0.001), relative 
to control normal bone marrow. The T-ALL subset contained ALL immature (pre), ALL 
immature (pro), ALL cortical, and ALL mature subclassess. Interestingly, significantly low 
levels of TRIB2 expression were associated with (pre-B) ALL with t(12;21) (p<0.001) 
(Figure 1A).  
As significant differences were observed in TRIB2 expression in the ALL subtype of 
leukaemias we sought to profile associated gene signatures with TRIB2 expression in 
these subsets further. TRIB2 expression was separated based on above the median 
versus below the median TRIB2 expression levels (see methods) and a one-way ANOVA 
was performed. We then performed unsupervised hierarchical clustering on the top 1000 
differentially expressed genes identified by the ANOVA analysis. Nearest–neighbour 
analysis revealed high TRIB2 expression associated specifically with the T-ALL subtype 
(Figure 1B). Genes associated with high TRIB2 ALL gene profile involved in T cell 
signalling and NOTCH1 signalling include CD7, ZAP70, LCK, CD3, CD28, LAT, SOCS2, 
PTPN(2, 4, 6, 7), NFAT, IK2F2, Deltex3 and T cell receptor genes TRD@ and TRBC1 
(supplementary data). Gene set enrichment analysis (GSEA) showed that the gene expression 
pattern of high TRIB2 ALL was significantly enriched for T cell receptor signalling pathway 
genes as described in the KEGG database (Figure 1C). An additional number of T cell 
pathways in the MsigDB showed significant enrichment in the high TRIB2 ALL gene list, 
and represenative genes from these pathways are shown in Figure 1D. Interestingly, 
functional annotation of the top 100 high TRIB2 gene neighbours showed enrichment of the 
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KEGG T cell receptor pathway and Haematopoietic cell lineage pathway in the ALL subsets 
(p value 7x10-11 and 7x10-5 respectively), in the AML subsets (p value 1.3x10-10 and 3x10-5 
respectively), and in normal bone marrow (p value 7x10-3 and 4x10-2 respectively). No 
pathways were identified in the top 100 low TRIB2 expressing gene lists (data not shown). 
These results are consistent with high TRIB2 expression being associated, and possibly 
contributing to the T cell phenotype of human ALL, AML and normal haematopoiesis.  
We next assessed the expression pattern of TRIB2 in human haematopoiesis during normal 
development. Using the recently published dataset profiling human haematopoietic 
compartments into 80 network modules (Novershtern et al, 2011) we analysed the expression 
levels of TRIB2 across the dataset (Figure 2A). The highest expression levels of TRIB2 in 
all haematopoietic subsets were in the T cell subsets. The T cell subsets contain naïve CD4+ 
and CD8+ cells, and effective and central memory CD4+ and CD8+ cells. There was an 
increase in TRIB2 expression as cells differentiated from the pre-B cell stage (containing 
early and pro-B cells) to the mature B cell stage (containing naïve and mature B cells). 
Interestingly, amongst the myeloid compartments TRIB2 expression levels were higher in 
granulocytes compared to monocytes, and compared to the dendritic cell (DC) subset. The 
haematopoietic stem cell (HSC) compartment expresses low levels of TRIB2 and as the cells 
commit to lineage development, TRIB2 expression appears to increase in the common 
myeloid progenitor (CMP), granulocyte-macrophage progenitor (GMP) and megakaryocyte 
erythroid progentior (MEP) populations. Overall, the levels of TRIB2 expression in human 
haematopoietic subsets is variable and highest in the lymphoid lineage, specifically the T cell 
compartment.  
To further dissect the expression profile of TRIB2 in haematopoiesis we identified the 
module networks in the normal haematopoietic system that were enriched for the high 
TRIB2 ALL gene profile. We performed GSEA comparing the high TRIB2 ALL gene list 
identified in the MILE study with all the modules in the haematopoietic dataset. Modules 
667, 757 and 829 were identified as being significantly enriched in the high TRIB2 ALL 
gene set, with additional modules with T cell and T/B cell induction patterns identified 
(Figure 2B and C). These modules had GATA3, LMO2, BCL11B, MBP2, FOXJ3, IRF3 and 
HBP1 genes as the top regulators and determined by GSEA to contain genes involved in T-
cell receptor signalling (Figure 2C)(Novershtern et al, 2011). Further GSEA analyses 
comparing the high TRIB2 gene neighbours in the haematopoietic dataset (i.e. high TRIB2 
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expression in normal haematopoiesis) with the modules in the dataset reveal that 13 modules 
are significantly enriched that have an induction pattern in T/B cells (data not shown). Of 
interest, TRIB2 itself is a member of module 769 defined in the Novershtern et al study 
which has an induction pattern in T/B cells and defined as the T/B cell module expressed in 
CD19+ B cells, CD4+ and CD8+ T cells and CD56+ NK cells. These analyses reveal that 
normal TRIB2 expression is highest in the lymphoid compartment, and the profile of high 
TRIB2 expression in ALL closely resembles the normal T cell profile. These data suggest 
that TRIB2 itself may function in lineage determination and/or the phenotype of the T cell 
compartment. 
As NOTCH1 plays a major role in T cell development and leukaemogensis, and TRIB2 is a 
NOTCH1 target gene, we analysed the TRIB2 expression pattern specifically in T-ALL with 
normal karyoptype. GSEA showed that the gene expression pattern of high TRIB2 T-ALL 
(gene list in supplementary data) identified in the MILE study was significantly enriched for 
NOTCH1 signalling pathways (Figure 3A), including NOTCH1 pathway genes Deltex2, 3, 
MAML1, 2, DLL1, JAGGED and ADAM10 (Figure 3B). We next addressed whether a 
relationship between TRIB2 and NOTCH1 mutations exist in T-ALL. A total of 60 
paediatric T-ALL patients were analysed for elevated TRIB2 expression that contained 
NOTCH1 and FBXW7 mutation rates of 17% and 10%, respectively. TRIB2 expression was 
measured by qRT-PCR and found to be significantly elevated in patients harbouring 
NOTCH1 and/or FBXW7 mutations versus patients wildtype for NOTCH1/FBXW7 (Figure 
3C). TRIB2 expression values were normalised to the geometric mean of two control genes 
(18s and ABL). The highest TRIB2 expression ratios were identified in patients T84 and 
T110 that harboured a NOTCH1 PEST domain and HD-C mutation respectively. All 
mutations were previously described (Erbilgin Y, 2010). Therefore, activation of the 
NOTCH1 pathway via NOTCH1 or FBXW7 mutation correlates with higher TRIB2 
expression levels as compared to T-ALL samples without NOTCH1 activation. Together 
these data show that high TRIB2 expression correlates with NOTCH1 signalling pathway 
and specifically in paediatric T-ALL with NOTCH1 and/or FBXW7 mutation and further 
supports a defining role of TRIB2 in the lymphoid lineage and lymphoid malignancies. 
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Discussion 
We demonstrate that high TRIB2 expression can enrich for gene sets of the T cell lineage, in 
normal haematopoietic development and across all subtypes of leukaemia. Specifically, high 
TRIB2 expression enriches for gene sets that define TCR signalling pathways in ALL and 
normal haematopoiesis. Moreover, high TRIB2 expression enriches for NOTCH1 signalling 
pathways specifically in T-ALL (not in all ALL subsets, data not shown) and correlates with 
activation of NOTCH1 in paediatric T-ALL. We previously identified a correlation between 
NOTCH1 mutations and high TRIB2 expression in AML (Wouters et al, 2007). The subtype 
of immature myeloid/T-lymphoid leukaemia reported originally as cluster 4 (Valk et al, 
2004) has subsequently been analysed to reveal that this subset is a biological entity distinct 
from both AML and T-ALL, and has unique epigenetic features (Figueroa et al, 2009). 
TRIB2 expression was originally identified to be elevated and a feature of the genetic 
signature of this cluster 4 (Keeshan et al, 2006; Wouters et al, 2007) along with NOTCH1 
mutations and T-lymphoid markers. Here we show that high TRIB2 expression alone can 
identify a T cell profile amongst all subtypes of leukaemia, and strongly correlates with 
activated NOTCH1 in paediatric T-ALL. While we do not know the mutation status of 
NOTCH1 or FBXW7 in the MILE study dataset which contains both paediatric and adult 
ALL samples, NOTCH1 mutations are reported to occur in ~50% of adult and paediatric T-
ALL. Despite the relatively low prevalence of NOTCH1 mutation in the cohort of paediatric 
T-ALL analyzed here (17% versus 34-71%), the prevalence of FBXW7 mutations are similar 
to other reports (10% versus 8-16%) (Kraszewska et al, 2012). Therefore our data support the 
association of high TRIB2 expression with an activated NOTCH1 phenotype, NOTCH1 
signalling and T cell profile in both adult and paediatric T-ALL and suggest that TRIB2 may 
represent a defining marker for malignancies with T cell features.  
Understanding the precise function of TRIB2 in the T cell lineage and specifically the 
NOTCH1 T-ALL phenotype will provide an important insight into our current understanding 
of TRIB2. High TRIB2 levels were identified in T-ALL with normal karyotype, and our 
results suggest that TRIB2 may function in the T cell phenotype of haematological 
malignancies. TRIB2 is an important modulator of MAPK signaling pathways and functions 
in the degradation of C/EBP family members, key regulators of the myeloid lineage. TRIB2 
is therefore an important regulator of pathways involved in the survival, proliferation and 
differentiation of haematopoietic cells. TRIB2 is also a direct target of NOTCH1, and 
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NOTCH1 activation leads to T-ALL in murine models and the human disease. Our data 
suggest that TRIB2 may indeed be involved in these processes.  
In our analysis of TRIB2 expression during normal haematopoiesis, we observed an increase 
in TRIB2 expression as cells differentiated from the pre-B cell stage (containing early and 
pro-B cells) to the mature B cell stage (containing naïve and mature B cells). We also see 
high levels of TRIB2 expression associated with ALL with t(1;19), which results in the E2A-
PBX1 fusion protein, one of the frequent recurring translocations in childhood ALL, present 
in about 5% of ALL cases, including 20–25% of pre-B ALL. Therefore, high TRIB2 
expression associated with a B and T-ALL in our study and TRIB2 itself is a defining 
member of the T/B cell module, present in CD19+ B cells, CD4+ and CD8+ T cells, identified 
by GSEA in the Novasthern et al study. These data suggest that TRIB2 functions in the 
lineage determination of T and B cells.  
No significant difference in TRIB2 expression was found in the mature B-ALL with t(8;14) 
subsets, whereas low TRIB2 expression levels were statistically different in the pre-B ALL 
with t(9;22) and for AML with t(11q23)/MLL compared to normal bone marrow. TRIB2 
expression in AML subtypes in this study therefore trend towards low TRIB2 expression 
levels with a relatively small subset of high TRIB2 expressing samples. Similarly, our 
original findings reported a specific subset of high TRIB2 expressing AMLs with a 
dysregulated C/EBPalpha and myeloid/lymphoid profile (Wouters et al, 2007). Functional 
annotation of the top 100 low TRIB2 expressing subsets however did not reveal any 
enrichment of specific pathways. Our findings here support the ability of high TRIB2 
expression to reveal a T cell profile in both T-ALL and AML. That TRIB2 expression levels 
can distinguish subtypes of leukaemia, for instance the T-ALL versus ALL with t(1;19) 
suggest that the molecular function of TRIB2 in different cell types with different aberrations 
will be of future interest. 
Remarkably TRIB2 gene expression profiling distinguishes the T cell lineage from other 
lineages in both normal and leukaemia datasets. Overexpression of TRIB2 in the murine 
model induced a block in myeloid differentiation and led to a myeloid leukaemia, yet normal 
granulocytes express TRIB2 at significantly higher levels compared to the HSC 
compartment. Perhaps the cell of origin overexpressing TRIB2 would determine the 
leukaemic phenotype that develops, and it would be interesting to test this further in in vivo 
models. In normal development TRIB2 is expressed highest in T cells, and these data suggest 
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that TRIB2 may in fact play a functional role in T cell lineage development and specifically 
associate with activated NOTCH1 signalling. TRIB2 knockout or knockdown approaches 
will lend further insight into the potential functional role of TRIB2 in lymphomagenesis.  
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Legends 
Figure 1: TRIB2 expression is highest in T-ALL and this subset is enriched for T cell 
signalling pathways (A) TRIB2 expression is highest in T-ALL with normal karyotype, in 
ALL with t(1;19) inversion, and lowest in ALL with t(12;21). TRIB2 (202478_at) expression 
was calculated from the MILE dataset (GSE13204) for each leukemic subtype. Values for 
each leukaemia subtype and normal bone marrow were plotted on a box plot with max and 
min whiskers. Intersecting line indicates position of mean. *** means p value is < 0.001 . 
StDev and SEM values are available to download as supplementary data. (B) T-ALL 
(red bar along top) is associated with high TRIB2 expression (green bar along top) in ALL. 
The ALL samples from the MILE study were separated based on above the median versus 
below the median TRIB2 expression levels of both TRIB2 probes (202478_at and 
202479_s_at), (2 = TRIB2 has above median levels of TRIB2 expression in both probe sets 
(green box). 1 = TRIB2 has above median levels of TRIB2 expression in one probe set 
(yellow), 0 = TRIB2 expression has below the median expression of TRIB2 in both probe 
sets (red)). Using Partek software 1-way ANOVA testing determined 1000 genes which were 
significantly differentially expressed between the high and low TRIB2 subsets (red and blue 
box along bottom bar, see supplementary data for gene list) with a p value < 5x10-12. These 
genes were then hierarchically clustered using Partek. (C) T-cell receptor signalling pathways 
are enriched in the high TRIB2 expressing subset of ALL. GSEA comparing the high TRIB2 
ALL subset from the MILE study and the KEGG T cell receptor signalling pathway dataset. 
The normalized enrichment scores (NES), p-value and q-value (FDR) are indicated on each 
plot. A p-value below 5% and a q-value below 25% indicate that the result is significant. (D) 
Heatmap of genes present in the high TRIB2 subset of ALL enriched in a number of 
statistically significant T-cell signalling and activation pathways identified from MSigDB 
(high expression in red and low in blue). A white box indicates that these genes are not 
present in that particular pathway.  
Figure 2: TRIB2 expression is highest in the T-cell compartment of the haematopoietic 
system. (A) TRIB2 expression analysis across normal human haematopoietic compartments. 
TRIB2 expression was assessed in the array dataset including human hematopoietic stem and 
progenitor cells, terminally differentiated cells, and intermediate state cells (GSE24759, 
noveshtern et al). Values for each compartment were plotted on a boxplot with max and min 
whiskers. Intersecting line indicates position of mean. StDev and SEM values are available 
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to download as supplementary data. (B and C) GSEA comparing the high TRIB2 ALL 
gene list from the MILE study and Module 667 (B) and 757 (C) haematopoietic 
compartments (Novershtern et al, 2011)(modules comprised of highly expressed genes in 
normal human T-cells and NK cells). The normalized enrichment scores (NES), p-value and 
q-value (FDR) are indicated on the plot. A p-value below 5% and a q-value below 25% 
indicate that the result is significant. (C) Table describing the induction pattern module 667, 
757 and 829. Classification of this module was determined by GSEA (Novershtern et al, 
2011) which identified that the genes present in the module are involved in T-cell receptor 
activity. 
Figure 3: High TRIB2 expression associates with NOTCH1 signalling in T-ALL. (A) 
NOTCH signalling pathways are enriched in the high TRIB2 expression subset of T-ALL. 
GSEAs comparing the high TRIB2 T-ALL subset of the MILE study and genes involved in 
NOTCH signalling, derived from the Reactome pathway database (left plot), based on the 
gene ontology (GO) database (middle plot) or derived from the KEGG pathway database 
(right plot). The normalized enrichment scores (NES), p-value and q-value (FDR) are 
indicated on each plot. A p-value below 5% and a q-value below 25% indicate that the result 
is significant. (B) Heatmap of genes present in the high TRIB2 subset of T-ALL enriched for 
the NOTCH signalling pathway identified from MSigDB (C) Elevated TRIB2 expression in 
paediatric patients harbouring mutated NOTCH1 and/or FBXW7 mutations. Relative 
expression ratios to the geometric mean of two housekeeping genes for TRIB2 gene in 
NOTCH1/FBXW7 mutant and wild type T-ALL patients. The relative expression levels for 
each sample was used to calculate the means (Avg), standard deviation (SD) and standard 
error of the mean (SEM) for each genotype. According to Student t test, p= 0.027 P value of 
0.05 or less (two sided) was considered to indicate a statistically significant.  
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